Regeneron Pharmaceuticals, Inc (REGN34) Fair Value & Analysis
Healthcare · BR · Market cap R$344B
Fair value as of: Jun 24, 2026
From 25 valuation models · updated 12 days ago
Share price +7.9% over the past month.
Price vs Fair Value (12 months)
12‑month range R$46.27 – R$69.00 · fair‑value band R$6.85 – R$13.21 · the R$53.50 price screens above the R$9.67 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Regeneron Pharmaceuticals, Inc (REGN34) currently trades at R$53.50, while our model-based Fair Value estimate is R$9.67 — implying the stock looks roughly 81.9% overvalued today. We read business quality at 64/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Regeneron Pharmaceuticals, Inc generated revenue of R$14.9B at a net margin of 29.7%. Revenue grew 19.0% year over year. It earns a return on equity of 14.6%. The stock trades on a trailing P/E of 15.8. Fundamentals as of Jun 24, 2026
Our scenario range runs from R$6.85 (bear case) to R$13.21 (bull case); at R$53.50, the current price sits above that range. The share trades about 27% below its 52-week high and 15% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -27% fair-value upside — at -82%, REGN34 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and …
Revenue & earnings trend
FY2022 – FY2025 · reported fiscal years
Regeneron Pharmaceuticals, Inc reported revenue of R$14.3B in FY2025 versus R$12.2B in FY2022, a compound +5.6%/yr. Reported net income was R$4.5B in FY2025, compounding +1.3%/yr from FY2022.
Is REGN34 fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$574.00 | R$357.63 | -38% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
| CSL Limited CSL | A$97.91 | A$100.60 | +3% |
| Celltrion, Inc 068270 | 168,500 KRW | 76,943 KRW | -54% |
| BioNTech SE B1NT34 | R$27.80 | R$23.67 | -15% |
| Moderna, Inc M1RN34 | R$14.75 | R$4.91 | -67% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
| WuXi Biologics (Cayman) Inc 2269 | HK$29.70 | HK$26.76 | -10% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Regeneron Pharmaceuticals, Inc (REGN34) undervalued?
What is the fair value of REGN34?
What is the quality score of REGN34?
What is the revenue of Regeneron Pharmaceuticals, Inc (REGN34)?
What is the net profit margin of REGN34?
Does Regeneron Pharmaceuticals, Inc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.